0001209191-23-056181.txt : 20231120
0001209191-23-056181.hdr.sgml : 20231120
20231120205559
ACCESSION NUMBER: 0001209191-23-056181
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231116
FILED AS OF DATE: 20231120
DATE AS OF CHANGE: 20231120
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Newton Charles W.
CENTRAL INDEX KEY: 0001866219
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40502
FILM NUMBER: 231424248
MAIL ADDRESS:
STREET 1: 46 FREDRICK AVENUE
CITY: ATHERTON
STATE: CA
ZIP: 94027
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Lyell Immunopharma, Inc.
CENTRAL INDEX KEY: 0001806952
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 833006753
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 201 HASKINS WAY
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650 695-0677
MAIL ADDRESS:
STREET 1: 201 HASKINS WAY
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-11-16
0
0001806952
Lyell Immunopharma, Inc.
LYEL
0001866219
Newton Charles W.
C/O LYELL IMMUNOPHARMA, INC.
201 HASKINS WAY
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Financial Officer
0
Common Stock
8729
D
Stock Option (right to buy)
1.87
2023-11-16
4
A
0
3612000
A
2031-02-04
Common Stock
3612000
3612000
D
Stock Option (right to buy)
6.24
2023-11-16
4
D
0
3612000
D
2031-02-04
Common Stock
3612000
0
D
Stock Option (right to buy)
1.87
2023-11-16
4
A
0
190000
A
2031-02-04
Common Stock
190000
190000
D
Stock Option (right to buy)
6.24
2023-11-16
4
D
0
190000
D
2031-02-04
Common Stock
190000
0
D
Stock Option (right to buy)
1.87
2023-11-16
4
A
0
516000
A
2031-02-04
Common Stock
516000
516000
D
Stock Option (right to buy)
6.24
2023-11-16
4
D
0
516000
D
2031-02-04
Common Stock
516000
0
D
Stock Option (right to buy)
1.87
2023-11-16
4
A
0
500000
A
2032-03-15
Common Stock
500000
500000
D
Stock Option (right to buy)
5.98
2023-11-16
4
D
0
500000
D
2032-03-15
Common Stock
500000
0
D
Includes 2,941 shares acquired on May 18, 2022, 5,787 shares acquired on May 18, 2023 and 1 share acquired on November 17, 2023 under the Issuer's 2021 Employee Stock Purchase Plan.
2,483,250 shares were vested as of November 16, 2023 and the remaining unvested shares will vest in equal monthly installments over the following twenty-seven months based on the original vesting commencement date.
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on November 16, 2023 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date.
Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options.
1/4 of the option shares vested on February 5, 2022, with the remaining option shares vesting in equal monthly installments over the following thirty-six months.
130,625 shares were vested as of November 16, 2023 and the remaining unvested shares will vest in equal monthly installments over the following twenty-seven months based on the original vesting commencement date.
311,750 shares were vested as of November 16, 2023 and the remaining unvested shares will vest in equal monthly installments over the following thirty-one months based on the original vesting commencement date.
1/48th of the total shares vest in equal monthly installments over the forty-eight months following June 16, 2021.
218,750 shares were vested as of November 16, 2023 and the remaining unvested shares will vest in equal monthly installments over the following thirty-nine months based on the original vesting commencement date.
12.5% of the option shares vested on August 9, 2022, with the remaining option shares to vest in equal monthly installments over the following forty-two months.
/s/ Hector Casab, as Attorney-in-Fact
2023-11-20